

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
23 January 2003 (23.01.2003)


PCT

(10) International Publication Number  
WO 03/006956 A2


- (51) International Patent Classification<sup>7</sup>: G01N 15/00 (72) Inventor; and  
(75) Inventor/Applicant (for US only): GLENCROSS, Deborah, Kim [ZA/ZA]; 17, 5th Avenue, 2198 Houghton (ZA).
- (21) International Application Number: PCT/IB02/02725
- (22) International Filing Date: 11 July 2002 (11.07.2002) (74) Agents: CLELLAND, Sandra, Luischen et al.; Spoor and Fisher, P.O. Box 41312, 2024 Craighall (ZA).
- (25) Filing Language: English (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (26) Publication Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
- (30) Priority Data: 01/5700 11 July 2001 (11.07.2001) ZA
- (71) Applicants (for all designated States except US): NATIONAL HEALTH LABORATORY SERVICE [ZA/ZA]; cnr De Korte and Hospital Streets, 2001 Braamfontein (ZA). UNIVERSITY OF WITWATERSRAND [ZA/ZA]; 1 Jan Smuts Avenue, 2001 Braamfontein (ZA).

[Continued on next page]

(54) Title: CELL ENUMERATION



(57) Abstract: The invention provides a method of enumerating the number of cells of a cell type in a cell sample by (a) counting the white blood cells in the cell sample to obtain the white blood cell population of the sample; (b) determining the proportion or percentage of the cells of the cell type in the white blood cell population in the sample; and (c) calculating the number of cells of the cell type in the sample. The cell type may be a lymphocyte sub-set selected from the group comprising CD4+ lymphocytes, CD 45 cells, CD19 cells, CD16 and CD56 positive cells, CD8 cells, CD3 cells or any combination thereof. The method is particularly useful in monitoring state or disease or condition where CD4+ lymphocytes or CD4+ T cells are monitored or counted.



WO 03/006956 A2

BEST AVAILABLE COPY



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- without international search report and to be republished upon receipt of that report

BEST AVAILABLE COPY

## CELL ENUMERATION

5

### BACKGROUND OF THE INVENTION

This invention relates to the enumeration of cells in a cell sample, for example in a bone marrow cell sample, a body fluid sample, a disaggregated tissue sample, a  
10 tissue fine needle aspiration sample or, in particular, a blood sample. More particularly, the invention relates to a method suitable for, but not limited to, enumerating the number of CD4+ lymphocytes in a blood sample.

There are several methods for performing cell counting which are currently  
15 available. The most popular method is flow cytometric cell testing. Non-flow cytometric methods are also available, although these methods are less widely used.

#### **Flow cytometric CD4+ T cell testing**

20 Two methods of flow cytometric CD4 testing are utilised worldwide for CD4+ T cell enumeration. The first method involves the use of two machines and is referred to as the dual or double platform method (DP) (1). This method involves the use of specific panels of antibodies including CD3, CD4, CD8, CD19, CD16, CD56, and CD45. Various fluorochrome combinations can be used to form either two, three or four  
25 colour combinations of antibody to constitute the various panels. Duplication of at least one measurement to ensure reproducibility e.g. CD3, is typically performed. In some instances it is recommended that CD14 expression is also used in the panel to exclude CD14 positive monocytes from the "lymphocyte" gate and ensure purity of the lymphocyte population studied.

30

The dual platform method makes use of a haematology analyser to obtain an absolute lymphocyte count (ALC) [which is obtained by multiplication of two independently measured parameters viz. the white cell count and the % lymphocytes

BEST AVAILABLE COPY

of the total white blood cell differential]. A flow cytometer is used to obtain a corresponding CD4 percentage (CD4%) of lymphocytes.

5 The CD4 antigen expressed on the surface of T cells and monocytes plays an important role in the MHC class II-restricted responses of specific T lymphocytes. It also serves as the major receptor of human immunodeficiency viruses (HIV).

CD45 is a trans-membrane protein tyrosine phosphatase (also called Leucocyte Common Antigen) that is expressed on all haematopoietic cells. Expression is at a  
10 higher density on lymphocytes whilst the expression is lower on other leukocytes like granulocytes and monocytes. In addition to the blood, bone marrow and lymphatics, since CD45 is found throughout the hematopoietic lineage, CD45 will be found wherever such cells constitute a significant portion of the tissue, e.g. spleen, thymus, and bone marrow.

15 Lymphocytes are defined by flow cytometry either through dual light scatter parameters, or alternatively (now considered the only recommended method in new guidelines) by the use of dual bright CD45 expression with side scatter properties. The lymphocyte population is used as the common denominator or reference point  
20 between the haematology and flow cytometry machines in order to calculate a CD4 T cell of total lymphocytes.

The absolute CD4 count is calculated by multiplying the CD4% (which can alternatively be defined as CD3+/ CD4+ T cells) of the total lymphoid population  
25 defined by flow cytometry by the ALC, which is then expressed as number of cells per microlitre, or number of cells  $\times 10^6/\ell$ , or the number of cells  $\times 10^9/\ell$ .

Inter-laboratory variation ranging between 15-44% is, however, described for the widely used dual platform method (greater than 60% of returns in a recent U.K.  
30 NEQAS Immunology shipment have been reported). Theoretically, in order that all laboratories measure lymphocytes equally, the U.K. NEQAS, CDC, NCCLS, and others have devised very specific guidelines (1) for use of a "Lymphosum". The "Lymphosum" itself is a method of identifying the total lymphoid population by flow cytometry including all T cells (CD3+), all B cells (CD19+) and all Natural Killer cells

BEST AVAILABLE COPY

(CD16+/ 56+), so that the sum of the individual components equals approximately 100% of lymphocytes.

Various gating strategies that include identification of bright CD45 positive cells  
5 (lymphocytes) have been recommended to ensure purity of the lymphoid population  
(2) and improve the quality of the assay, but this is not widely practiced in many  
countries. The practice of abbreviated panels, including only CD3/ CD4 and CD8 is  
based loosely on international guidelines. It is practiced largely due to cost  
10 containment, and has limited quality control, especially on samples which are older  
than 6-24 hours, when cell disintegration results in poor cellular definition and hence  
problems occur with accurate identification and subsequent gating of lymphocytes.  
Use of CD3, CD4 and CD8 antibodies in a single tube to determine the percentage of  
CD4 positive T cells is therefore not recommended for use (1) as there is no means  
15 in the abbreviated panel of CD3, CD4 and CD8 only to validate the purity or  
completeness of the lymphocyte gate.

From the haematology analyser perspective, white blood cell counts and especially  
automated differential counts should ideally be performed within 6 hours of  
venesection and preferably within 24 hours. There is currently no known  
20 haematology analyser manufactured that reliably facilitates white cell and/ or white  
blood cell differential counting after 36 hours after blood collection.

Further, different haematology analysers use different methods of identifying  
lymphocytes and show variation in ALC reporting according to the specifications of  
25 the analyser, even on fresh samples less than 6 hours old. Although the guidelines  
for identifying lymphocytes by flow cytometry are relatively clear, to date no  
recommended or universal method of identifying lymphocytes or other different types  
of white blood cell on a haematology analyser exists, despite there being existing  
knowledge of very specific differential expression of CD45 on lymphocytes. ALC  
30 white blood cell differential counts are therefore neither quality controlled nor  
standardised between laboratories and results are therefore unreliable and not  
directly comparable between laboratories. Because the CD4 count is calculated from  
the ALC in the dual platform system, it follows that the inaccuracies of the ALC are  
translated to the CD4 count. Thus, the error in each independent step of each the

separate systems in the dual platform method is multiplied at each subsequent step in the calculation.

In spite of the relatively wide inter-laboratory variation of CD4 result reporting, the dual platform flow cytometry system remains the most widely used and preferred system for CD4 testing. One of the main problems of the dual platform method lies in the identification of lymphocytes as the common denominator or reference point between the two platforms. An Absolute Lymphocyte Count (ALC) is a highly variable parameter between laboratories. Currently, although white blood cell (WBC) counts are well quality controlled, both internally on the instruments themselves and externally on various quality assessment schemes, white blood cell *differential* counting methods and techniques of identifying lymphocytes on various haematology analysers are neither quality controlled or standardised. As ALCs are currently used as the common denominator and mainstay of dual platform system CD4 counting, it therefore follows that the documented variability of ALC reporting is carried over into CD4+ T cell result reporting.

#### Single platform testing

The single platform method (SP) of measuring CD4+ T cells uses flow cytometry only, and both the cell counting and the identification of the CD4+ T cells are performed on the same instrument, a flow cytometer. It is recommended due to the improved reproducibility of laboratory results, the inter-laboratory variation having been reported as varying between 10-18%.

There are several options for performing single platform CD4 testing. One option includes the use of a flow cytometer with a volumetric precision counting facility, e.g. the Ortho Cytoron *Absolute* (Ortho Diagnostic Systems, USA) but this instrument is no longer manufactured. The second option utilises beads as a reference standard from which the cells themselves can be counted. The beads are added to the sample in a known concentration, either during manufacture or during sample preparation, in a specified volume, to a similar volume of blood and counted alongside the cells of interest on a flow cytometer. Bead-based counting, although less variable between laboratories, is, however, more technically intensive and relies heavily on accurate, precise pipetting, and also on the technical skills of the

operator. Duplication of testing is also recommended to assess pipetting error and ensure accuracy of counting. This increases further the costs of bead-based testing.

- 5 Simplified, smaller single platform flow cytometers dedicated to CD4 enumeration (FACSCount, BDS, San Jose, CA, USA) are also widely used. Although these instruments are considerably cheaper than flow cytometers, reagents costs for these instruments are more costly than for ordinary flow cytometry, thereby also prohibiting their use in many laboratories.

10

An additional problem of both the single platform and dual platform systems is that of the increased costs associated with "Lymphosum" testing. Unfortunately the obviously less expensive "CD4 only" alternatives do not offer sufficient built-in quality control to ensure accuracy and precision of individual sample testing.

15

#### **Alternative technologies for CD4+ T cell determination.**

There are also several alternative non-flow cytometric technologies for CD4+ T cell counting available. These include the Dynabead™ assay, Coulter Cytospheres Assay TRAx assay (and Microvolume Fluorimetry The Absolute Lymphocyte Count (ALC) has also been proposed as an alternative to CD4 enumeration where an ALC of less than 1000 cells/ $\mu$ l is used a substitute for a CD4+ T cell count of 200/ $\mu$ l or less. Poor correlation of these parameters, however, has been shown, and it has been suggested that an ALC substitute does not offer meaningful information for individual patient management.

25

The current dual methods of CD4 testing are therefore impractical and/or expensive, and do not provide results which are sufficiently accurate. A need thus exists to provide a method which is simple to perform, accomodates existing technologies and is more accurate than currently methods employed.

30

BEST AVAILABLE COPY

### SUMMARY OF THE INVENTION

According to a first embodiment of the invention, there is provided a method of enumerating the number of cells of a cell type in a cell sample, the method comprising the steps of:

- 5       counting the white blood cells in the cell sample to obtain the white blood cell population of the sample;
- determining the proportion or percentage of the cells of the cell type in the white blood cell population in the sample; and
- 10       calculating the number of cells of the cell type in the sample.

The number of cells of the cell type in the sample may be calculated by relating the proportion or percentage of the cells of the cell type to the white blood cell population in the sample.

15       The cell type may be a lymphocyte sub-set, and in particular, a lymphocyte sub-set selected from the group comprising CD4+ lymphocytes, CD 45 cells, CD19 cells, CD16, and CD56 positive cells, CD8 cells, CD3 cells or any combination thereof. More particularly, the lymphocyte sub-set may be CD4+ lymphocytes. The CD4+ lymphocytes may be CD4+ T cells.

20       The sample may be whole unlysed blood, unfractionated, fractionated or lysed whole blood. Alternatively, the sample may be whole unlysed bone marrow, unfractionated, fractionated or lysed whole bone marrow.

25       Counting the white blood cells (CD45 positive leucocytes) in the sample will naturally involve identifying the white blood cells in the sample, and any suitable known, conventional or established method may be used for such counting (and identification), using any suitable haematology analyser or flow cytometer. For example, identification of nuclear nucleic acid (DNA) staining may be employed as a method of counting the white blood cell population (i.e. the white cell count) in the sample. The white blood cell population in the sample may be defined by flow cytometry, either immunophenotypically as CD45+ cells, or, using a technique substantially similar to DNA staining, as nucleated cells. The white cell population

30



may be counted directly using total CD45 expression to obtain a total white cell count, when incorporating beads as a single platform reference standard in the sample or using a volumetric precision counter.

- 5 Actual calculating of the number of CD4+ T cells in the sample may be performed by multiplying the white blood cell population in the sample by a factor, which is the proportion of CD4+ T cells in the white blood cell population when the proportion of CD4+ T cells of the white blood cell population is expressed as a fraction. If the proportion of CD4+ T cells in the white blood cell population is expressed as a percentage, then the white blood cell population will be multiplied by a factor which is a hundredth of the percentage ( $\% \times 10^{-2}$ ).
- 10

The invention thus provides a dual-platform method of establishing (but not limited to) the number of CD4+ T cells in the sample, using two separate parameters.

15

- Counting the white blood cells in the sample may, as indicated above, be by means of a suitable haematology analyser. Any suitable haematology analyser may be employed, examples being those available under the trade names GenS™, CELL-DYN™ 4000, and XE2100™, manufactured respectively by Beckman Coulter, Inc. (GenS™), Abbott (CELL-DYN™ 4000) and Sysmex Corporation (XE2100™). In turn, determining the proportion of CD4+ T cells in the white blood cells in the sample may, as indicated above, be by means of a suitable flow cytometer. Any suitable flow cytometer may be employed, examples being those available under the trade names EPICS™ XL and FACSCalibur™, manufactured respectively by Beckman Coulter, Inc. (EPICS™ XL) and BD Biosciences (FACSCalibur™).
- 20
- 25

- While any suitable technique for counting the white blood cells in the sample may be employed, counting said white blood cells may, for example, be by a size discrimination technique, by an impedance measuring technique, or precision volumetric counting.
- 30

Similarly, while any suitable technique for determining the proportion of CD4+ T cells in the white blood cells in a sample may be employed, determining the proportion of

CD4+ T cells in the white blood cells in the sample may, for example, be by means of flow-cytometric 90°/side scatter with CD4 expression. While the counting of the white blood cells and the determining of the proportion of CD4+ T cells in the sample may be carried out on separate instruments, namely a haematology analyser and a flow cytometer, it may be possible to combine the functions of such instruments so that both the white blood cell count and the determination of the proportion or percentage of CD4+ T cells of the white blood cells can conveniently be carried out on a single or common instrument.

10 In a particular embodiment of the invention a dual-platform (i.e. double- or twin-platform) method may be employed, involving two separate instruments to obtain the CD4+ T cell population (i.e. the absolute CD4+ T cell count) in the sample, namely a haematology analyser to obtain the white cell count and a flow cytometer to obtain the fraction or percentage of CD4+ T cells. The white cell count obtained from the haematology analyser is then multiplied by the CD4+ T cell fraction or percentage (as indicated above), measured as a fraction of the population of white blood cells (defined as the CD45+ (positive-expressing cells) obtained from the flow cytometer. This calculation facilitates the generation of the absolute CD4+ T cell count.

20 Thus, for example, a Beckman Coulter GenS™ haematology analyser may be used to obtain a white cell count on a blood sample, followed by measurement of the CD4+ T cell fraction or percentage of the white blood cell population (defined by the CD45+ expression thereof) using a Beckman Coulter EPICS™ XL flow cytometer, on the same blood sample.

25 Instead, a single-platform method may be employed, involving a single instrument, the total white cell count and the CD4+ T cell fraction or percentage of the total white cell population being obtained on a single instrument (which may be either a flow cytometer or a haematology analyser). This may be effected by counting the white blood cells directly on a haematology analyser having a facility for fluorescence measurement which can be altered to effect measurement of the fraction or proportion of CD4+ T cells of the total white cell population. Alternatively, the CD4+ T cell fraction or percentage of the total white cell population may be

measured directly on a flow cytometer for a blood sample, which flow cytometer has had a suitable (commercially available) bead counting preparation (such as Beckman Coulter Flow-Count™ Fluorospheres) added thereto, the beads being counted simultaneously and being used as a standard from which the absolute  
5 number of CD4+ T cells can be calculated.

The method may additionally comprise one or more of the following steps:

calculating the number of lymphocytes in the sample by relating the proportion or percentage of high density CD45++ bright cells and low side scatter  
10 cells, a component of which is CD4 positive lymphocytes, to the white blood cell population in the sample, thereby to establish the population of lymphocytes in the sample;

calculating the number of monocytes in the sample by relating the proportion or percentage of moderate density CD45++ cells and medium side scatter cells, and  
15 dim moderate density CD4 cells, to the white blood cell population in the sample, thereby to establish the population of monocytes in the sample; and

calculating the number of granulocytes in the sample by relating the proportion or percentage of dim low density CD45+ cells and CD4 negative cells and high side scatter cells to the white blood cell population in the sample, thereby to  
20 establish the population of granulocytes in the sample.

CD45 and CD4 may be combined either for use with a dual or a single platform system to provide at least a three-part (3-part) or at best, a five-part (5-part) white blood cell differential including the identification of granulocytes, monocytes,  
25 lymphocytes, basophils and eosinophils, in addition to the identification of CD4+ lymphocytes (T cells). Both percentages and absolute counts of each of the individual latter mentioned cellular compartments can be generated, as described above. This may be effected by counting the white blood cell compartments directly on a haematology analyser having a facility for fluorescence measurement which  
30 can be altered to effect measurement of the fraction or proportion of relevant cells of the total white cell population e.g. granulocytes, and the like. Alternatively, the particular cell fraction or percentage of the total white cell population may be measured directly on a flow cytometer for a blood sample, which flow cytometer has

BEST AVAILABLE COPY

had a suitable (commercially available) bead counting preparation (such as Beckman Coulter Flow-Count™ Fluorospheres) added thereto, the beads being counted simultaneously and being used as a standard from which the absolute number of the component cells e.g. granulocytes and the like can be calculated.

5

According to a second embodiment of the invention, there is provided a kit for use in enumerating the number of CD4+ T cells in a sample according to the method described above, the kit including antibodies for use in the method and instructions for performing the method. The kit may include software for analysis of flow  
10 cytometry or haematology analyser data.

The antibodies may be CD4 and/or CD45 antibodies.

The kit may also include computer software for at least partially performing the  
15 method of cell enumeration described above.

According to a further embodiment of the invention, there is provided a machine readable medium comprising instructions, which when executed by a machine, cause the machine to perform, at least partially, the method steps substantially as  
20 described above. The machine readable medium may be configured for use in conjunction with a flow cytometer and/or a haematology analyser, and may include instructions for analysis of flow cytometry data.

According to yet a further embodiment of the invention, there is provided a method  
25 of monitoring the immune status of a patient with HIV or other immune deficiency condition or disease, the method including the step of enumerating the number of CD4+ lymphocytes or CD4+ T cells in a cell sample from the patient by a method substantially as described above. In particular, the method may be used to determine or monitor the patient's response to antiretroviral treatment.

30

BEST AVAILABLE COPY

**BRIEF DESCRIPTION OF THE FIGURES**

- Figure 1** shows histograms of dual platform total white blood cell (CD45) assisted CD4 T cell enumeration:
- 5            Figure 1a shows a histogram of capture of total CD45 positive events (all white blood cells); and
- Figure 1b shows a histogram of gated CD45 positive events with identification of CD4 positive lymphocytes.
- Figure 2** shows histograms of single platform total white blood cell (CD45) assisted CD4 T cell enumeration:
- 10           Figure 2a shows a histogram of capture of total CD45 positive events (all white blood cells), excluding fluorospheres;
- Figure 2b shows a histogram of gated CD45 positive events with
- 15           identification of CD4 positive lymphocytes; and
- Figure 2c shows a histogram of capture of total CD45 positive events (all white blood cells).
- Figure 3** shows histograms of a 5-part white blood cell differential and CD4+ lymphocytes based on use of CD45 and CD4:
- 20           Figure 3a shows a histogram of capture of total CD45 positive events (all white blood cells), including lymphocytes, monocytes, granulocytes and basophils; and
- Figure 3b shows a histogram of gated CD45 positive events with
- 25           identification of CD4 positive lymphocytes, monocytes, granulocytes and eosinophils.

**DETAILED DESCRIPTION OF SOME EMBODIMENTS OF THE INVENTION**

30

The invention will now be described, by way of non-limiting illustration, with reference to the following explanatory examples, with reference to the accompanying drawings.

**BEST AVAILABLE COPY**

**Example 1: Dual-platform method**

5 A full blood sample was collected from a consenting adult in ethylene diamine tetra-acetic acid ( $K_3EDTA$ ). This sample was delivered to the laboratory within 6 hours of venesection. Upon receipt in the laboratory the sample was subjected to a white blood cell count performed on a Beckman Coulter GenS™ haematology analyser. A white cell count of  $4.80 \times 10^9/l$  was obtained.

10 Appropriate external quality assessment and internal quality control as recommended by the supplier was performed daily on this instrument to ensure that the white cell count was accurate and precise.

15 After the white blood cell count was obtained, blood taken from the same sample was prepared for flow cytometric analysis. Flow cytometric preparation involved dispensing a well-mixed  $100 \mu l$  aliquot of whole blood into the bottom of a  $12 \times 75$  mm test tube. Anti-CD4 phycoerythrin (PE) monoclonal antibodies and CD45 Fluorescein-isothiocyanate (FITC) monoclonal antibodies were added (both obtained from Immunotech, Beckman Coulter, Inc., Miami, Florida) according to the supplier's  
20 recommendations and incubated for 10 minutes at room temperature, in the dark.

The tube containing the  $100 \mu l$  of blood with the added CD45 and CD4 antibodies was then prepared for flow cytometric analysis on a Beckman Coulter Q-Prep/ImmunoPrep™ Reagent System and Workstation, as directed by the supplier. This  
25 preparative step included adding a red blood cell lysing agent, a stabiliser and a fixative. The sample was then analysed on a Beckman Coulter EPICS™ XL flow cytometer as set forth hereunder. Appropriate internal quality control including proper alignment and standardisation for light scatter and fluorescence intensity, as well as colour compensation, as recommended by the supplier was performed daily  
30 on this instrument to ensure that the flow cytometry results were accurate and precise.

BEST AVAILABLE COPY

Thus total leucocytes were first identified on a [CD45 FITC vs. side scatter (SS)] display (Region A in Figure 1a). All CD45 positive gated events in Region A (the total number/ population of leucocytes) were then displayed in Figure 1b, containing only the CD45positive cells, using a [CD4 PE vs. SS] display where CD4++ (high density).low side scatter lymphoid cells, were identified (Region B in Figure 1b). A  
5 CD4+ lymphocyte (T cell) percentage of 16.5 % was noted.

The absolute CD4+ lymphocyte (T cell) count was obtained by multiplying the white cell count obtained from the haematology analyser by the CD4+ T cell fraction  
10 obtained by flow cytometry, i.e.  $4.8 \times 10^9/\ell$  multiplied by 16.5% divided by 100. This gave  $0.792 \times 10^9$  CD4+ lymphocytes (T cells)/ $\ell$  (or 792 CD4+ lymphocytes (T cells)/ $\mu\ell$ ).

In this method, the total leucocytes served as a common denominator or reference  
15 point for the dual-platform absolute CD4+ T cell counting, instead of using the lymphoid population as the common denominator or reference point, which is the existing state of the art for the dual platform methodology.

The gating strategy employed also made possible the calculation of the CD4+ T cell  
20 percentage of total lymphocytes, i.e. the number of events in Gate B (Figure 1b) divided by the number of events in Gate C (Figure 1a). Thus, 752 CD4+ events noted in Gate B were divided by 1416 CD45+ bright events noted in Gate C (Figure 1a), i.e.  $752/1416$  (0.531 or 53.1%). This CD4 cell percentage of total lymphocytes, irrelevant to the present invention, was nevertheless available in case  
25 it was clinically relevant, e.g. in paediatric cases.

The gating strategy employed also made possible the calculation of each of the individual components of the full white blood cell differential of this sample. In this analysis, total leucocytes were first identified on a [CD45 FITC vs. side scatter (SS)]  
30 display (Region A in Figure 3a). All CD45 positive gated cells (i.e. gated events) in Region A (the total number of leucocytes) were then displayed in Figure 3b containing only the CD45 positive cells, using a [CD4 PE vs. SS] display. These displays included lymphocytes (Figures 3a and 3b, Gate C), monocytes (Figures 3a

BEST AVAILABLE COPY

and 3b, Gate E), basophils (Figure 3a, Gate F), granulocytes (Figures 3a and 3b, Gate G), and eosinophils (Figure 3b, Gate H).

5 The number of events in each of these respective gates (i.e. the number of events in Gate C (Figures 3a and 3b), Gate E (Figure 3a and 3b), Gate F (Figure 3b) and Gate G (Figure 3a and 3b) and Gate H (Figure 3b), divided by the number of events in Gate A (Figure 3a) were thus used to generate the respective percentages of the individual white blood cell differential components.

10 Thus, the following calculations were possible:

Lymphocyte percentage:

1416 high density CD45 brightly positive events with low side scatter, and of which a component could be CD4 positive, noted in Gate C (Figure 3a), were  
15 divided by 4750 CD45 positive events noted in Gate A (Figure 3a), i.e.  $1416/4750$  (0.298 or 29.8%).

Monocyte percentage:

380 moderate density CD45 moderately bright positive events with moderate  
20 side scatter and moderate density CD4 expression or positivity, noted in Gate E (Figures 3a and 3b), were divided by 4750 CD45 positive events noted in Gate A (Figure 3a), i.e.  $380/4750$  (0.080 or 8.0%).

Basophil percentage:

25 51 low density CD45 dimly positive events with low side scatter, and negative CD4, in noted Gate F (Figure 3a), were divided by 4750 CD45 positive events noted in Gate A (Figure 3a), i.e.  $51/4750$  (0.010 or 1.0%).

Granulocyte percentage :

30 2758 low density CD45 dimly positive events with high side scatter (and negative CD4 expression) noted in Gate G (Figures 3a and 3b), were divided by 4750 CD45 positive events noted in Gate A (Figure 3a), i.e.  $2759/4750$  (0.581 or 58.1%).

BEST AVAILABLE COPY



Eosinophil percentage:

145 moderate density CD45 moderately bright positive events with very high side scatter and some weak autofluorescence noted on FL2, noted in Gate H were divided by 4750 CD45 positive events noted in Gate A (Figure 3a), i.e.  
5 144/ 4750 (0.031 or 3.1%).

The absolute counts of each of the components of the white blood cell differential including Gates C, E, F, G and H was obtained by multiplying the white cell count obtained from the haematology analyser by the respective white blood cell  
10 differential fraction obtained by flow cytometry.

Thus, the following absolute calculations were possible:

Absolute lymphocyte count

15 4.8 x 10<sup>9</sup>/ℓ multiplied by 29.8% (Figure 3a, Gate C) divided by 100. This gave  
1.430 x 10<sup>9</sup> lymphocytes/ℓ (or 1430 lymphocytes /μℓ).

Absolute monocyte count

20 4.8 x 10<sup>9</sup>/ℓ multiplied by 8.0% (Figure 3a and 3b, Gate E) divided by 100. This  
gave 0.384 x 10<sup>9</sup> monocytes/ℓ (or 384 monocytes /μℓ).

Absolute basophil count

25 4.8 x 10<sup>9</sup>/ℓ multiplied by 1.0% (Figure 3a, Gate F) divided by 100. This gave  
0.048 x 10<sup>9</sup> basophils/ℓ (or 48 basophils /μℓ).

Absolute eosinophil count

4.8 x 10<sup>9</sup>/ℓ multiplied by 3.1% (Figure 3b, Gate H) divided by 100. This gave  
0.149 x 10<sup>9</sup> eosinophils/ℓ (or 149 eosinophils /μℓ).

30 Absolute granulocyte count

4.8 x 10<sup>9</sup>/ℓ multiplied by 58.1% (Figure 3a and 3b, Gate G) divided by 100.  
This gave 2.789 x 10<sup>9</sup> granulocytes/ℓ (or 2789 granulocytes /μℓ).

BEST AVAILABLE COPY

**Example 2: Single-platform method**

A full blood sample was collected in K<sub>3</sub>EDTA from a consenting adult patient. This sample was delivered to the laboratory within 6 hours of venesection. Upon arrival  
5 in the laboratory the sample was prepared for flow cytometric analysis. Flow cytometric preparation involved dispensing (by reverse pipetting) a well-mixed 100 µl aliquot of the sample (whole blood) into the bottom of a 12 X 75 mm test tube.

Anti-CD4 PE monoclonal antibodies and CD45 FITC monoclonal antibodies were  
10 added (both obtained from Immunotech, Beckman Coulter, Inc., Miami, Florida) according to the supplier's recommendations and incubated for 10 minutes at room temperature, in the dark. The tube containing the 100 µl of blood with the added CD45 and CD4 antibodies was then prepared for flow cytometric analysis using the above mentioned Q-Prep/ ImmunoPrep™ Reagent System and Workstation, as  
15 directed by the supplier.

After this whole blood preparation step, which included adding a red cell lysing agent, a stabiliser and a fixative, commercially available bead reagents (Flow-Count™ Fluorospheres obtained from Beckman Coulter, Inc., Miami, Florida) were  
20 added to the sample as directed by the supplier. This Fluorosphere addition step involved using a very well mixed 100 µl aliquot of the Flow-Check™ Fluorospheres. The assayed concentration of the Fluorospheres was stated to be 1000 µl. The Fluorospheres were added by a reverse pipetting technique with careful attention not to pipette air bubbles. Good reverse pipetting technique was crucial to the  
25 accuracy and precision of these test results. The sample was analysed within 2 hours of the addition of the Fluorospheres and was well mixed prior to flow-cytometric analysis.

The sample was then analysed on a Beckman Coulter EPICS™ XL flow cytometer  
30 until 1000 Fluorospheres were counted. Appropriate internal quality control including proper alignment and standardisation for light scatter and fluorescence intensity as well as colour compensation, as recommended by the supplier was performed daily on this instrument to ensure that flow cytometry results were

BEST AVAILABLE COPY

accurate. In this analysis, total leucocytes were first identified on a [CD45 FITC vs. side scatter (SS)] display (Region A in Figure 2a). All CD45 positive gated cells (i.e. gated events) in Region A (the total number of leucocytes) were then displayed in Figure 2b containing only the CD45 positive cells, using a [CD4 PE vs. SS] display  
5 where CD4++, low side scatter lymphoid cells were identified (Region B in Figure 2b). The Fluorosphere population was shown in a separate histogram of [Forward Scatter (abbreviated as FS) vs Fluorospheres] the latter of which were detected on log scale of FL4 (fluorescence detector number 4) (Region D, Figure 2c).

10 The absolute CD45 positive cell count (total white blood cell count) was calculated as directed by the Fluorosphere manufacturer's instructions (Beckman Coulter Flow-Count™), i.e. total number of cells counted divided by the total number of Fluorospheres counted, and then multiplied by the Flow-Count™ Fluorosphere assayed concentration, gave the absolute count/ $\mu\text{l}$ .

15

The CD45 positive leucocyte count was therefore calculated as follows:

The Region A count of 4737 (total CD45positive cells counted) was divided by the Region D count of 1000 (total Fluorospheres counted), and then multiplied by 1000/ $\mu\text{l}$  (the Fluorosphere assayed concentration), which gave a white cell count of  
20 4737/ $\mu\text{l}$  or  $4.737 \times 10^9/\text{l}$  (the absolute CD45 positive leucocyte or white cell count). The absolute CD4+ T cell count was obtained by multiplying this calculated CD45positive white cell count by the percentage of CD4++ low side-scatter lymphocytes (T cells) counted within the CD45 positive+ leucocyte population (Region B, Figure 2b i.e. 4737/ $\mu\text{l}$  multiplied by 16.2% (i.e. by 0.162). This gave 766  
25 CD4 lymphocytes (T cells)/ $\mu\text{l}$  (or  $0.766 \times 10^9$  CD4+lymphocytes (T cells)/l).

In this method, the total CD45+ positive leucocyte count served as the base line for the absolute CD4+ T cell counting instead of using the total lymphoid population (defined by light scatter or by CD45 bright or CD3 positive lymphocyte count as the  
30 base line, which is the single platform methodology.

Alternatively, the CD4 lymphocyte (T cell) count can be directly calculated. This is achieved by taking the number of events in Figure 2b, Region B (766) and dividing

BEST AVAILABLE COPY

this number by the Figure 2c, Region D count (1000 -total Fluorospheres counted), and then multiplying by 1000/ $\mu\text{l}$  (the Fluorosphere assayed concentration), which gave 766 CD4 lymphocytes (T cells)/ $\mu\text{l}$  or  $0.766 \times 10^9$  CD4+ lymphocytes (T cells)/ $\ell$ , which is equivalent to the absolute CD4+ T cell count).

5

The gating strategy employed also made possible the calculation of the CD4+ T cell percentage of total lymphocytes, i.e. the number of cells in Gate B (Figure (IV)) divided by the number of cells in Gate C (Figure III). Thus, 766 events noted in Gate B were divided by 1421 CD45 ++ bright events noted in Gate C, i.e. 766 divided by  
10 1421 (0.539 or 53.9%). This value was not, however, used in the generation of the CD4+ count, and was merely extra information available in case the CD4 percentage of lymphocytes was clinically relevant, e.g. in paediatric cases.

In a similar fashion to the dual platform method, this single platform methodology  
15 can be used to calculate the respective percentages and absolute counts for a 5-part white blood cell differential on this sample. The method is identical to that described for the dual platform technology except that beads or an appropriate single platform technology including volumetric Ortho Cyturon <sup>TM</sup> counting is used as the directling counting mechanism and is applicable to whole or lysed blood  
20 samples.

Advantages of the invention, particularly as described with reference to the above examples, are that the use of a count of the white blood cell population incorporating the use of CD45 expression as the basis for calculating the number of CD4+ T cells  
25 in cell samples facilitates accurate determinations after delays of up to several days after sample collection. Both CD45 and CD4+ T cell expressions are preserved with only minor losses of fluorescence intensity for greater than 120 hours, even after loss of forward scattering properties. Indeed, both the CD45+ leucocyte- and the side-scattering features of white blood cells promise to be retained for up to 7 days  
30 after sample collection. By virtue of including both the CD45+ leucocyte- and side-scattering parameters, technical errors can be avoided and irrelevant cellular events arising from, for example, monocytes (specifically related to absolute CD4

BEST AVAILABLE COPY

lymphocyte (T cell) counts) or red blood cells, can be excluded while relevant lymphoid cells, e.g. those with apoptotic scatter features, can be included.

Additional use of the invention with respect to the identification of the components of the white blood cell differential count and the enumeration thereof can significantly alter the present haematology analyser state of the art. Given that there is adequate retention of both the CD45 and CD4 molecules several days after the time of venesection as described above and that the basis of measuring the cells is by CD45 and CD4, a total white blood cell count and full differential with absolute counts can be supplied several days after venesection as opposed to the 24 hour limit given by most haematology analyser manufacturers. This feature adds a facility of delayed testing of several days and a new dimension which is not currently a feature of state of the art haematology analysers. The method is therefore suitable for generating white cell counts with full 5-part differentials and absolute differential counts on samples which are already several days old.

The approach of the present invention is particularly amenable to paediatric samples where small quantities of blood are available. In the absence of CD45+ leucocyte staining, unlysed and nucleated red blood cells may drastically interfere with the definition of both CD4+ T lymphocyte absolute counts and CD4+ T lymphocyte fraction- or percentage values. In infants and children the CD4+ T lymphocyte percentage counts are used as the clinically relevant parameter because of the age-dependent variability of the CD4+ T absolute counts. Use of CD45+ leucocyte counts as a basis facilitates use of precise CD4+ T lymphocyte fraction- or percentage values by identifying the CD4+ + T cells as a function the bright CD45+ + leucocyte cells.

The main advantage of the CD45 assisted dual platform CD4 enumeration system is that it represents the only reliable quality controlled system for CD4 lymphocyte counting in a single test tube. Whereas single platform systems of counting including bead based or volumetric precision delivery systems have been reported as offering better accuracy, they rely on the duplication of the reading of at least one of the components of the duplication (i.e. CD3 duplicate) to reproduce and quality assess the absolute count (bead based counting, especially, is prone to error

BEST AVAILABLE COPY

introduced by errors of pipetting). The DP CD45 assisted dual platform "PanLeucogating" CD4 enumeration system utilises the white cell count which has the "built-in" quality control through quality control of the white cell count on the haematology analyser itself, thus leading to the conclusion of good quality control in  
5 a single test tube. External isotype controls to assess non-specific binding of monoclonal antibody isotype are also not required in this system.

While the invention is relatively easy to perform, the applicant expects that the calculation of the CD4+ T cell enumeration or other white blood cell differential  
10 component populations as previously described, need not be performed manually, and a computer program for performing this calculation may be provided. The computer program may include computer executable instructions suitable for use on a flow cytometer and/or haematology analyser.

15 A kit may also be provided to enable a user to perform the invention, the kit including one or more antibodies and instructions for performing the invention. The antibodies would typically be CD4 and/or CD45 antibodies. The kit may also include the computer program, or include instructions for use in conjunction with the program.

20 The method of the present invention specifically for CD4 lymphocyte enumeration avoids the need for Lymphocyte referencing, is relatively robust, reproducible between laboratories and accurate, while being easy to use and comparatively inexpensive and easily implemented. The method is also suitable for use on  
25 samples which are already several days old.

BEST AVAILABLE COPY

**References:**

1. CDC-Centers for Disease Control and Prevention 1997 Revised  
5 guidelines for performing CD4+ T cell determinations in persons  
infected with human immunodeficiency virus (HIV). MMWR 1997;  
46:1-29.
2. Schnizlein-Bick C, Mandy F, O'Gorman M, Paxton H, Nicholson JKA,  
10 Hultin LE, Gelman RS, Wilkening C and Livnat D. Use of CD45  
gating in three and four color flow cytometric immunophenotyping:  
Guideline from the NIAID, Division of AIDS. Cytometry 2002, 50(2);  
46-52.
3. Glencross DK, Scott L, Jani I.V., Barnett D and Janossy G. CD45  
15 assisted PanLeucogating for Accurate, Cost Effective Dual Platform  
CD4+ T cell Enumeration. Cytometry Clinical Cytometry, 2002  
Special Issue - CD4: 20 years and Counting: 50 (2); 69-77.

BEST AVAILABLE COPY

## CLAIMS

1. A method of enumerating the number of cells of a cell type in a cell sample,  
the method comprising the steps of:
  - 5 counting the white blood cells in the cell sample to obtain the white blood cell population of the sample;
  - determining the proportion or percentage of the cells of the cell type in the white blood cell population in the sample; and
  - calculating the number of cells of the cell type in the sample.
- 10 2. A method according to claim 1, wherein the number of cells of the cell type in the sample is calculated by relating the proportion or percentage of the cells of the cell type to the white blood cell population in the sample, thereby to establish the population of cells of the cell type in the sample.
- 15 3. A method according to either of claims 1 or 2, wherein the number of cells of the cell type in the sample is calculated by multiplying the white blood cell population in the sample by a factor which is the proportion of the cells of the cell type in the white blood cell population when the proportion of the cells of the cell type of the white blood cell population is expressed as a fraction.
- 20 4. A method according to any one of claims 1 to 4, wherein the number of cells of the cell type is calculated using either one of or both of a haematology analyser and a flow cytometer.
- 25 5. A method according to any one of claims 1 to 4, wherein the white blood cells are counted by a size discrimination technique, an impedance measuring technique or precision volumetric counting.
- 30 6. A method according to any one of claims 1 to 5, wherein the cell type is a lymphocyte sub-set.
7. A method according to claim 6, wherein the lymphocyte sub-set is selected from the group comprising CD4+ lymphocytes, CD 45 cells, CD19 cells,

BEST AVAILABLE COPY



CD16 and CD56 positive cells, CD8 cells, CD3 cells or any combination thereof.

- 5 8. A method according to either of claims 6 or 7, wherein the lymphocyte subset is CD4+ lymphocytes.
9. A method according to claim 8, wherein the CD4+ lymphocytes are CD4+ T cells.
- 10 10. A method according to any one of claims 1 to 9, which additionally comprises one or more of the following steps:
  - 15 calculating the number of lymphocytes in the sample by relating the proportion or percentage of high density CD45++ bright cells and low side scatter cells, a component of which is CD4 positive lymphocytes, to the white blood cell population in the sample, thereby to establish the population of lymphocytes in the sample;
  - 20 calculating the number of monocytes in the sample by relating the proportion or percentage of moderate density CD45++ cells and medium side scatter cells, and dim moderate density CD4 cells, to the white blood cell population in the sample, thereby to establish the population of monocytes in the sample; and
  - 25 calculating the number of granulocytes in the sample by relating the proportion or percentage of dim low density CD45+ cells and CD4 negative cells and high side scatter cells to the white blood cell population in the sample, thereby to establish the population of granulocytes in the sample.
- 30 11. A method according to claim 10, wherein CD45 and CD4 antibodies are used to identify at least an absolute lymphocyte count, an absolute monocyte count and an absolute granulocyte count when the number of cells of the cell type are enumerated.
12. A method according to either of claims 10 or 11, wherein an absolute eosinophil count is also identified by relating the proportion or percentage of moderate density CD45+ cells, CD4 negative cells and very high side scatter

cells to the white blood cell population in the sample, thereby to establish the population of eosinophils in the sample.

- 5 13. A method according to any one of claims 10 to 12, wherein an absolute basophil count is also identified by relating the proportion or percentage of low density dim CD45+ cells, CD4 negative cells and low side scatter cells to the white blood cell population in the sample, thereby to establish the population of basophils in the sample.
- 10 14. A method according to any one of claims 1 to 13, for use in monitoring the immune status of a patient infected with HIV or other immune deficiency state or disease or condition where CD4+ lymphocytes or CD4+ T cells are monitored or counted.
- 15 15. A method according to any one of claims 10 to 14, wherein the sample is whole unlysed blood, unfractionated, fractionated or lysed whole blood.
16. A method according to any one of claims 10 to 14, wherein the sample is whole unlysed bone marrow, unfractionated, fractionated or lysed whole bone marrow.
- 20 17. A kit for use in enumerating the number of cells of a cell type in a sample according to the method of any one of claims 1 to 16, which includes antibodies for use in the method and instructions for performing the method.
- 25 18. A kit according to claim 17, wherein the antibodies are CD4 and/or CD45 antibodies.
- 30 19. A kit according to either one of claims 17 or 18, which includes machine readable instructions for at least partially performing the method of cell enumeration according to any one of claims 1 to 16.

BEST AVAILABLE COPY

20. A machine readable medium comprising instructions, which when executed by a machine, cause the machine to perform the method steps of any one of claims 1 to 16.
- 5 21. A machine readable program according to claim 20, which is configured for use in conjunction with a flow cytometer and/or haematology analyser.
22. A machine readable medium according to either of claims 20 or 21, which includes instructions for analysis of flow cytometry data.
- 10 23. A method of monitoring the immune status of a patient with HIV or other immune deficiency condition or disease, the method including the step of enumerating the number of CD4+ lymphocytes or CD4+ T cells in a cell sample from the patient by a method according to any one of claims 1 to 16.
- 15 24. A method according to claim 23, wherein the patient's immune status is determined or monitored to determine the patient's response to antiretroviral treatment.
- 20 25. A method according to claim 1, substantially as herein described with reference to any one of the illustrative examples.
26. A method according to claim 21, substantially as herein described with reference to any one of the illustrative examples.

25

BEST AVAILABLE COPY

1/4




Figure 1a




Figure 1b

BEST AVAILABLE COPY

2/4




Figure 2a




Figure 2b

BEST AVAILABLE COPY


$\frac{3}{4}$ 

Figure 2c

BEST AVAILABLE COPY

4/4




Figure 3a




Figure 3b

BEST AVAILABLE COPY

**ABSTRACT**

The invention provides a method of enumerating the number of cells of a cell type in a cell sample by (a) counting the white blood cells in the cell sample to obtain the  
5 white blood cell population of the sample; (b) determining the proportion or percentage of the cells of the cell type in the white blood cell population in the sample; and (c) calculating the number of cells of the cell type in the sample. The cell type may be a lymphocyte sub-set selected from the group comprising CD4+ lymphocytes, CD 45 cells, CD19 cells, CD16 and CD56 positive cells, CD8 cells,  
10 CD3 cells or any combination thereof. The method is particularly useful in monitoring the immune status of a patient infected with HIV or other immune deficiency state or disease or condition where CD4+ lymphocytes or CD4+ T cells are monitored or counted.

**BEST AVAILABLE COPY**